Drugs Made In America Acquisition (DMAAR) EPS (Basic) (2025)

Drugs Made In America Acquisition (DMAAR) posted EPS (Basic) of -$0.21 for Q4 2025, down 222.71% on a QoQ basis from $0.17 in Q3 2025.

Drugs Made In America Acquisition (DMAAR) EPS (Basic) (2025) Analysis & Trends

Drugs Made In America Acquisition's EPS (Basic) history runs 1 years deep, the most recent figure standing at -$0.21 for Q4 2025.

Quarterly EPS (Basic) changed N/A year-over-year to -$0.21 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $0.23 (changed N/A YoY) and the FY2025 annual result came in at $0.23, up 805.2% from the prior year.
EPS (Basic) was -$0.21 for Q4 2025 at Drugs Made In America Acquisition, down from $0.17 in the prior quarter.
Across five years, EPS (Basic) topped out at $0.18 in Q2 2025 and bottomed at -$0.21 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	SIM Acquisition Corp. I	314.52 Mn	314.52 Mn	-	0.02
2	Thayer Ventures Acquisition	208.29 Mn	208.29 Mn	-	-0.02
3	Newbury Street II Acquisition	185.26 Mn	185.26 Mn	-	0.06
4	Dynamix	178.78 Mn	178.78 Mn	-	0.06
5	Hallmark Venture	103.01 Mn	102.76 Mn	-	-
6	Voyager Acquisition	99.58 Mn	99.45 Mn	-	-
7	Gores Holdings X	95.80 Mn	95.37 Mn	-	0.05
8	Archimedes Tech SPAC Partners	89.88 Mn	89.88 Mn	-	0.55
9	Cohen Circle Acquisition	80.05 Mn	80.05 Mn	-	0.18
10	Drugs Made In America Acquisition	1.46 Mn	1.46 Mn	-	-0.21

Download Data